Health Care [ 3/12 ] | Biotechnology [ 26/74 ]
NASDAQ | Common Stock
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections.
The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with MerusN. V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies.
The company was incorporated in 1987 and is headquartered in Foster City, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 6, 24 | 2.02 Decreased by -11.79% | 1.55 Increased by +30.32% |
| Aug 8, 24 | 2.01 Increased by +21.08% | 1.60 Increased by +25.62% |
| Apr 25, 24 | -1.32 Decreased by -196.35% | -1.49 Increased by +11.41% |
| Feb 6, 24 | 1.72 Increased by +2.99% | 1.76 Decreased by -2.27% |
| Nov 7, 23 | 2.29 Increased by +20.53% | 1.92 Increased by +19.27% |
| Aug 3, 23 | 1.66 Increased by +5.06% | 1.64 Increased by +1.22% |
| Apr 27, 23 | 1.37 Decreased by -35.38% | 1.54 Decreased by -11.04% |
| Feb 2, 23 | 1.67 Increased by +142.03% | 1.50 Increased by +11.33% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 7.54 B Increased by +7.02% | 1.25 B Decreased by -42.52% | Increased by +16.61% Decreased by -46.29% |
| Jun 30, 24 | 6.95 B Increased by +5.30% | 1.61 B Increased by +54.45% | Increased by +23.23% Increased by +46.67% |
| Mar 31, 24 | 6.69 B Increased by +5.26% | -4.17 B Decreased by -512.87% | Decreased by -62.37% Decreased by -492.25% |
| Dec 31, 23 | 7.12 B Decreased by -3.71% | 1.43 B Decreased by -12.87% | Increased by +20.08% Decreased by -9.51% |
| Sep 30, 23 | 7.05 B Increased by +0.11% | 2.18 B Increased by +21.86% | Increased by +30.92% Increased by +21.72% |
| Jun 30, 23 | 6.60 B Increased by +5.42% | 1.04 B Decreased by -8.65% | Increased by +15.84% Decreased by -13.35% |
| Mar 31, 23 | 6.35 B Decreased by -3.61% | 1.01 B Increased by +8.32 K% | Increased by +15.90% Increased by +8.63 K% |
| Dec 31, 22 | 7.39 B Increased by +2.00% | 1.64 B Increased by +329.32% | Increased by +22.20% Increased by +320.89% |